

### AMENDMENTS TO THE CLAIMS

- 1-26. (Canceled).
27. (Currently amended) An isolated polypeptide comprising:
- (a) the amino acid sequence of the polypeptide of shown in Figure 4 (SEQ ID NO:7);
  - (b) the amino acid sequence of the polypeptide of shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;
  - (c) the amino acid sequence of the extracellular domain of the polypeptide of shown in Figure 4 (SEQ ID NO:7);
  - (d) the amino acid sequence of the extracellular domain of the polypeptide of shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide; or
  - (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203661.
28. (Currently amended) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the polypeptide of shown in Figure 4 (SEQ ID NO:7).
29. (Currently amended) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the polypeptide of shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide.
30. (Currently amended) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the extracellular domain of the polypeptide of shown in Figure 4 (SEQ ID NO:7).
31. (Currently amended) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the extracellular domain of the polypeptide of shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide.
32. (Previously presented) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203661.
33. (Previously presented) A chimeric polypeptide comprising a polypeptide according to Claim 27 fused to a heterologous polypeptide.
34. (Currently Amended) The chimeric polypeptide of Claim 33, wherein said heterologous polypeptide is ~~an epitope~~ a tag polypeptide or an Fc region of an immunoglobulin.

Appl. No. : 10/032,996  
Filed : December 27, 2001

35. (Currently amended) An isolated polypeptide having at least 95% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of shown in Figure 4 (SEQ ID NO:7);
- (b) the amino acid sequence of the polypeptide of shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide of shown in Figure 4 (SEQ ID NO:7);
- (d) the amino acid sequence of the extracellular domain of the polypeptide of shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203661;

wherein said isolated polypeptide is overexpressed in lung or colon tumors compared to normal lung or colon tissue, respectively, or wherein said isolated polypeptide is encoded by a nucleic acid which is amplified in lung or colon tumor compared to normal lung or colon tissue, respectively.~~retains the biological activity of a native PRO539 polypeptide.~~

36. (Canceled).

37. (Previously presented) The isolated polypeptide of Claim 35, wherein said amino acid sequence identity is at least 96%.

38. (Previously presented) The isolated polypeptide of Claim 35, wherein said amino acid sequence identity is at least 97%.

39. (Previously presented) The isolated polypeptide of Claim 35, wherein said amino acid sequence identity is at least 98%.

40. (Previously presented) The isolated polypeptide of Claim 35, wherein said amino acid sequence identity is at least 99%.

41-45. (Canceled).

46. (New) A chimeric polypeptide comprising a polypeptide according to Claim 35 fused to a heterologous polypeptide.

47. (New) The chimeric polypeptide of Claim 46, wherein said heterologous polypeptide is a tag polypeptide or an Fc region of an immunoglobulin.